Frank Torti
Principal @ New Enterprise Associates
Menlo Park, United States
Frank Torti is a Series A investor at New Enterprise Associates in Menlo Park focused on Biotechnology and Health Care. Frank Torti is the Vant Chair at Roivant Sciences. Frank received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Frank Torti invests in
BiotechnologyHealth CareTherapeuticsPharmaceuticalMedical
Stages Frank Torti invests in
Series ASeries CSeries BSeries D
Countries Frank Torti invests in
United StatesChina
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (33%)
- Health Care 3 (25%)
- Therapeutics 3 (25%)
- Pharmaceutical 3 (25%)
- Medical 2 (17%)
Stage
- Series A 3 (25%)
- Series C 3 (25%)
- Series B 2 (17%)
- Series D 1 (8%)
Country
- United States 5 (42%)
- China 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes,both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue. | $100M / Series C / Jul 01, 2020 | ||
| Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes,both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue. | $75M / Series C / Dec 19, 2018 | ||
| Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $70M / Series C / Sep 19, 2018 | ||
| Xoc utilizes state-of-the-art receptor characterization technology and cutting-edge medicinal chemistry to identify product candidates and develop novel therapies to meet the goal of providing improved safety and efficacy for patients. Xoc manages the clinical and regulatory risk in our development programs by leveraging the extensivepharmacological history of compounds similar to their product candidates.The name “Xoc” is derived from a term in the Mayan language and is pronounced “shock”. | $30M / Series A / Feb 06, 2018 | ||
| OrphoMed is a San Francisco Bay Area pharmaceutical company focused on the development of novel first-in-class therapeutic dimer conjugates based on its proprietary DIMERx™ platform technology. The company is leveraging its DIMERx™ technology to address the problem of visceral hypersensitivity and pancreatitis in the treatment of gastrointestinaldisorders and the unmet medical needs in the treatment of both peripheral neuropathic and systemic nociceptive pain.The lead candidate ORP-101 is a peripherally acting sodium ion channel blocker (Nav 1.7), mu agonist/kappa antagonist dimer. The molecule does not cross the blood brain barrier and, unlike other opioids that constrict the sphincter of Oddi, ORP-101, when given intravenously in animal studies, has instead been shown to relax the sphincter. The former attribute implies no abuse potential and the latter minimizes the risks of pancreatitis and/or abdominal pain related to sphincter of Oddi constriction. These two attributes, in combination with the well-understood pharmacology of ORP-101, make the molecule a suitable candidate for chronic treatment of conditions associated with visceral and somatic hypersensitivity and hyperalgesia. Therefore we have positioned ORP-101 for two non-overlapping indications: the oral form for colonic hyperalgesia and gastric dysmotility in IBS-D and the parenteral form for the treatment of peripheral neuropathic pain. The potential clinical benefits are backed by compelling data from validated animal models.The company is also developing potent non-opioid and opioid conjugates to treat acute and chronic nociceptive pain. The non-opioid analgesic conjugate is designed to be non-ulcerogenic and liver-safe and, therefore, has the potential to reshape the pain market served by acetaminophen and NSAIDs. Similarly, the opioid conjugate is designed to be orally active and have a lower potential for dependence than currently available opioids.DIMERx™ technology results in conjugates designed to preserve the receptor pharmacology of their individual constituents, but to have therapeutic profiles well suited for different clinical indications. The components of the conjugates have all been previously proven to be safe and effective for other indications and, therefore, the conjugates have reduced developmental risks. The DIMERx™ conjugates are considered to be new molecular entities and have composition of matter intellectual property protection. | $39M / Series A / May 24, 2017 | ||
| Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes,both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue. | $44M / Series B / Jun 23, 2016 | ||
| Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $5M / Series B / Feb 03, 2016 | ||
| Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $38M / Series C / Jan 27, 2016 | ||
| Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $37M / Series B / Oct 14, 2015 | ||
| Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent smallmolecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, it's lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.The company was established in 2009 and is headquartered in Malvern, Pennsylvania, United States. | $4.7M / Series A / Mar 19, 2015 | ||
| See all 12 investments → | |||
Co-Investors
New Enterprise Associates is a venture capital firm that invests in technology and healthcare startups. The firm engages with entrepreneurs at various stages of business development, providing support from initial funding to public offerings. The company focuses on the technology and healthcare industries.
New Enterprise Associates Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Sharata
Associate
|
|||
Anthony Florence
General Partner
|
|||
Bala Deshpande
Sr. Managing Director, India
|
|||
Hilarie Koplow-McAdams
Venture Partner
|
|||
Jay Graf
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Investors
21,234 investors
Health Care VC Funds
36,465 investors
Biotech VC Funds
20,850 investors
Biotechnology VC Funds
18,763 investors
Medical VC Funds
18,263 investors
Health Care Investors in United States
23,845 investors
FAQ
What does Frank Torti invest in?
Frank Torti invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Frank Torti?
Public channels for Frank Torti include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Frank Torti last invest?
The most recent investment recorded for Frank Torti closed in Jul 2020. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
